> english version Imprint

 

Impressum

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Telefon: +49 6221 4294830
Telefax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: https://www.sciomics.de
Sciomics GmbH wird vertreten durch: Geschäftsführer Dr. Christoph Schröder

 

Registergericht: Amtsgericht Mannheim
Handelsregister
Registernummer: HRB716969

Umsatzsteuer-Identifikationsnummer gemäß § 27a Umsatzsteuergesetz: DE289272460

 

Urheberrecht

Alle Inhalte der Internetpräsenz der Sciomics GmbH sind urheberrechtlich geschützt. Dies gilt für Texte wie auch Fotos, Grafiken sowie PDF-Dokumente.
Jede Vervielfältigung oder Verbreitung dieses Internetangebotes oder auch von Inhalten, Auszügen, Dateien oder anderen Teilen davon, zum Beispiel zum Nachdruck, zur Kopie in andere Internetseiten oder zur Weitergabe in elektronischer Form, bedarf der schriftlichen Genehmigung der Sciomics GmbH.

 

Haftung

Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

 

 

 

Imprint

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Phone: +49 6221 4294830
Fax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: https://www.sciomics.de
Sciomics GmbH is represented by: Geschäftsführer Dr. Christoph Schröder

 

Register jurisdiction: Amtsgericht Mannheim
Commercial Register
Registration number: HRB716969

Umsatzsteuer-Identifikationsnummer (VAT identification number) according to §27a of the Umsatzsteuergesetz (UStG, Sales Tax Law): DE289272460

 

Copyright

The layout, texts, text fragments and graphics used and any other contents on the homepage protected by copyright law. All rights reserved.

 

Liability

Links have been proved during setup. Since information on the WWW is subject of current change Sciomics accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.
This disclaimer is not intended to contravene any requirements laid down in applicable national law nor to exclude liability for matters which may not be excluded under that law.


 

 

 

 

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Anti-cancer activity and mechanism of action of metformin in endometrial cancer cells

| March 2021 | Scientists at Heidelberg University Hospital characterized the protein profile response of an endometrial cell line to Metformin treatment and hyperinsulinemia  with our scioDiscover platform:

"The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity.

With the presented data, we contribute to a better understanding of the anti-cancer activity of metformin as well as its underlying mechanism of action in EC cells."

Lange, C. et al. (2021) ‘Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line’, PLoS ONE 16(3):e0248103. https://doi.org/10.1371/journal.pone.0248103 

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

Testimonials

Dr. Joachim Lupberger 

Institute for Viral and Liver Disease, Inserm U1110, University of Strasbourg, LabEx HepSYS, Strasbourg, France

"Our lab is focusing on the identification of minimal-invasive biomarkers for liver disease progression. A challenge of our humanized animal models for liver disease is the low volume of blood samples available, which did not pose any problem for the analysis. I was pleased by the prompt, friendly, and uncomplicated contact and was impressed by the results and the thorough report we received. The overall quality was excellent, which made us to continue using the service of Sciomics for follow-up projects analyzing patient material."

Product: scioPhospho

 

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

 

Tweets

  • 4 days ago

    Happy to have supported Prof. Wagner's, Uni Heidelberg, research project. Our broad spectrum array scioDiscover ena… https://t.co/wTTVFw3cp5

  • 12 days ago

    A fruitful collaboration with Francesco P. Fiorentino @fistaral et al. got published in Int J Mol Sci: BET-Inhibito… https://t.co/cQvVu3sSxi

  • 22 days ago

    RT @car_endo: BioEndoCar @car_endo is delighted to announce that the #targeted #metabolomics measurements were finished. We obtained the co…

  • 33 days ago

    Tune into our CEO Dr. Christoph Schröder’s @ChristophSch78 exciting talk: “Prediction of severe COVID-19 disease –… https://t.co/FrAB76Rij7

  • 47 days ago

    Join us at this year's BIO Digital virtual conference and learn how we can push your research forward with our prot… https://t.co/8eKhFB8Hmm